Executive Interviews

  1. Accelerating Drug Development With Real World Data 12/1/2023

    Think real-world data’s only application is clinical trials? Think again. Savvy early-stage biotechs are leveraging RWD in their formative stages, long before entering the clinic, to drive critical efficiencies in drug discovery and development.

  2. Manufacturing And Supply Chain: Making Space Between A Rock And A Hard Place 12/1/2023

    Biopharmaceutical companies can’t afford to halt production lines due to manufacturing violations next year. Manufacturing and supply chain processes will require fresh thinking and flexibility in 2024.

  3. Building A Business Model For Novel Antibiotics 11/1/2023

    In the challenging development space for novel antibiotics, Spero Therapeutics is using partnership, external validation, and formulation science to develop drugs treating bacterial infections both rare and common.

  4. The Power Couple Behind Krystal Biotech 11/1/2023

    Krish and Krishnan, the husband-and-wife team that founded and leads Krystal Biotech, cleared a path to market for the first ever topical and redosable gene therapy.

  5. Using AI To Find And Develop Safer Medicines 10/2/2023

    Montai Health CEO Margo Georgiadis is using what she’s learned at McKinsey, Discover, Google, Mattel, and Ancestry to reinvent drug discovery and development, with a focus on long-term safety.

  6. Life Biosciences Grows Up: A Q&A With Jerry McLaughlin 10/2/2023

    Through the boom and bust of anti-aging buzz cycles, Life Biosciences has continued its focus on epigenetic reprogramming with an increasingly focused pipeline and development strategy.

  7. Taking A Fresh Approach To Finance At BMS 9/1/2023

    A rising star in BMS’s finance department, Tatiana Simonelli, SVP, finance commercialization at BMS discusses her path to senior leadership, and how talent diversity can boost business results.

  8. Biotech Veteran Pushes New Science And Regulatory Change 9/1/2023

    Ashvattha Therapeutics CEO Jeff Cleland hopes to bring hydroxyl dendrimer therapeutics to market for the first time, while also pushing for policy and regulatory change as an advocate for BIO.

  9. To America, A New Biopharma Model 9/1/2023

    Ketan Mehta, founder and CEO of Tris Pharma. Mehta came to the U.S. in the late 1970s. Since then, he has built a career in pharma and, more recently, an entirely new company with a triad of businesses — platform technology licensing, generic medicines, and new drug development.

  10. Novo Nordisk Returns To Growth, With Growing Pains 8/1/2023

    Novo Nordisk’s return to growth is largely due to an explosion of demand for its anti-obesity products. However, challenges with supply and insurance coverage persist.